Open in APP

Ropinirole Patch Versus Placebo, Ropinirole Extended‐Release Tablet in Advanced Parkinson's Disease


Background A dopamine agonist patch is an important treatment option for PD. Objectives A randomized, double‐blind, parallel‐group, placebo‐controlled trial was conducted to evaluate superiority of ropinirole hydrochloride patch over placebo and noninferiority to ropinirole hydrochloride extended‐release tablet. Methods PD patients using levodopa received ropinirole patch (up to 64 mg/d), ropinirole tablets (up to 16 mg/d), or placebo once‐daily (double‐dummy technique). The primary endpoint was the change from baseline in the total score for the UPDRS Part III (on state) at week 16. Results The change of the least squares mean (95% confidence interval) in the UPDRS Part III total score was –9.8 (–10.8 to –8.7) with ropinirole patch, –4.3 (–5.8 to –2.8) with placebo, and –10.1 (–11.2 to –9.1) with ropinirole tablet. The difference between the ropinirole patch and placebo groups was –5.4 (–7.3 to –3.6), demonstrating superiority of the patch over placebo. The difference between the ropinirole patch and tablet groups was 0.3 (–1.2 to 1.8). The upper limit of the 95% confidence interval was smaller than the noninferiority limit of 2.5, demonstrating noninferiority of ropinirole patch to ropinirole tablet. In all three groups, most adverse events were mild or moderate and there were no serious safety concerns. Conclusions Once‐daily ropinirole patch was effective in advanced PD patients, having demonstrated superiority over placebo and noninferiority to ropinirole tablet, without causing serious safety problems. Ropinirole patch can be an alternative option for PD patients. © 2020 International Parkinson and Movement Disorder Society

Keywords: Parkinson's disease, randomized controlled trial, ropinirole hydrochloride, transdermal drug delivery system, Unified Parkinson's Disease Rating Scale Part III (on state)

Author: Nobutaka Hattori, Hideki Mochizuki, Kazuko Hasegawa, Masahiro Nomoto, Eiji Uchida, Takaaki Terahara, Koji Okawa, Hiroyuki Fukuta
Journal: Movement Disorders( IF:8.1 )   Time:2020-09-16
DOI:10.1002/mds.28071    [Quote]
Link:     Article     PDF

Comments    Read:4

Ftracker is a frontier tracker.
专业学术信息平台,免费并及时为您提供全球范围内各大期刊的最新学术信息。 “关键词内容订制”,”期刊浏览”,”数据库检索”,”期刊下载”,”评论讨论”。
Mobile App
IOS search "Ftracker" in AppStore
Ftracker学术犬: 970207982

文献求助群Ftracker: 698420805

新冠病毒交流Ftracker: 878107029

植物基因功能Ftracker: 556178713

©2020 Ftracker